Small intestinal bacterial overgrowth and non‐alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy

We aimed to determine if there was a higher incidence of small intestinal bacterial overgrowth (SIBO) in non‐alcoholic fatty liver disease (NAFLD) than in patients without NAFLD. Moreover, we assessed whether patients with significant fibrosis (SF) had a higher incidence of SIBO compared with patients with non‐significant or no liver fibrosis.

[1]  R. Gani,et al.  The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience , 2019, BMC Gastroenterology.

[2]  M. Kukla,et al.  Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease , 2019, Clinical and experimental hepatology.

[3]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[4]  E. Quigley.  The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO) , 2019, Current Gastroenterology Reports.

[5]  F. Domper Bardají,et al.  An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity. , 2019, Revista Espanola de Enfermedades Digestivas.

[6]  Z. Torabi,et al.  Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth , 2018, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[7]  D. S̆timac,et al.  Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? , 2018, World journal of gastroenterology.

[8]  U. Ghoshal,et al.  Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture , 2017, Indian Journal of Gastroenterology.

[9]  U. Ghoshal,et al.  Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders. , 2017, Gastroenterology clinics of North America.

[10]  D. S̆timac,et al.  Nonalcoholic fatty liver disease - A multisystem disease? , 2016, World journal of gastroenterology.

[11]  G. Targher,et al.  Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. , 2016, Journal of diabetes and its complications.

[12]  A. Gasbarrini,et al.  Diagnosis and treatment of small intestinal bacterial overgrowth , 2016, Expert review of gastroenterology & hepatology.

[13]  C. Greenhill.  Obesity: Gut microbiota, host genetics and diet interact to affect the risk of developing obesity and the metabolic syndrome , 2015, Nature Reviews Endocrinology.

[14]  U. Kilic,et al.  Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease , 2015, European journal of gastroenterology & hepatology.

[15]  Y. Chawla,et al.  Small intestinal bacterial overgrowth and toll‐like receptor signaling in patients with non‐alcoholic fatty liver disease , 2015, Journal of gastroenterology and hepatology.

[16]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[17]  C. Couto,et al.  The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease , 2014, Nutrients.

[18]  L. Eusebi,et al.  Gut microbiota and metabolic syndrome. , 2014, World journal of gastroenterology.

[19]  R. Aggarwal,et al.  Gut microbiota and liver disease , 2014, Journal of gastroenterology and hepatology.

[20]  E. Murphy,et al.  The gut microbiota and the liver. Pathophysiological and clinical implications. , 2013, Journal of hepatology.

[21]  P. Scully,et al.  Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8 , 2011, Digestive Diseases and Sciences.

[22]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[23]  Jaroslav Kvetina,et al.  Small intestinal bacterial overgrowth syndrome. , 2010, World journal of gastroenterology.

[24]  S. Msika,et al.  High Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Morbid Obesity: A Contributor to Severe Hepatic Steatosis , 2008, Obesity surgery.

[25]  B. Lacy,et al.  Small intestinal bacterial overgrowth: a comprehensive review. , 2007, Gastroenterology & hepatology.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.